Multicenter, open-label, phase 2 study of CPX-1 (irinotecan HCl: floxuridine) liposome injection in patients with advanced colorectal carcinoma
Phase of Trial: Phase II
Latest Information Update: 09 Aug 2017
At a glance
- Drugs Irinotecan/floxuridine (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- 17 May 2012 Actual patient number is 59 according to ClinicalTrials.gov.
- 17 May 2012 Actual end date (Dec 2008) added as reported by ClinicalTrials.gov.
- 17 May 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.